CH:CURE ETF Price & Analysis
CURE ETF Chart & Stats
CHF23.63
--
Market closed
CHF23.63
--
Day’s Range― - ―
52-Week RangeCHF15.07 - CHF24.53
Previous CloseCHF23.63
VolumeN/A
Average Volume (3M)400.00
AUM24.86M
NAV28.26
Expense Ratio0.35%
Holdings Count50
Beta0.79
Inception DateSep 02, 2022
Next Dividend Ex-DateN/A
Dividend Yield
(―)Shares OutstandingN/A
Standard DeviationN/A
10 Day Avg. Volume65
30 Day Avg. Volume400
AlphaN/A
ETF Overview
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD
The VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD, with ticker GB:CURE, is a cutting-edge investment vehicle designed for those seeking to capitalize on the transformative potential of the genomics and healthcare innovation sectors. This ETF strategically focuses on a sector that is at the forefront of scientific advancement, emphasizing a thematic niche that goes beyond traditional healthcare investments by targeting companies pioneering in genomics and related technologies.
By investing in GB:CURE, investors gain exposure to a diversified portfolio of firms that are driving breakthroughs in genomic sequencing, genetic data analysis, and precision medicine, all of which hold the promise to revolutionize healthcare outcomes and efficiencies. The fund is meticulously curated to include companies that demonstrate robust innovation and growth potential, ensuring that investors are not just part of the healthcare story, but are positioned at its most innovative and disruptive frontier.
As a sector-focused thematic ETF, GB:CURE offers a unique opportunity to align investment portfolios with future-forward healthcare solutions, catering to investors who are keen on participating in the long-term growth trajectory of genomics and healthcare innovation. This ETF serves as a gateway to the promising intersection of technology and healthcare, making it an appealing choice for those with a vision to invest in the next wave of medical advancement.
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD (CURE) Fund Flow Chart
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD (CURE) 1 year Net Flows: CHF13M
CURE ETF News
CURE ETF FAQ
What was CH:CURE’s price range in the past 12 months?
CH:CURE lowest ETF price was CHF15.07 and its highest was CHF24.53 in the past 12 months.
What is the AUM of CH:CURE?
As of Oct 12, 2026 The AUM of CH:CURE is 24.86M.
Is CH:CURE overvalued?
According to Wall Street analysts CH:CURE’s price is currently Undervalued.
Does CH:CURE pay dividends?
CH:CURE does not currently pay dividends.
How many shares outstanding does CH:CURE have?
Currently, no data Available
Which hedge fund is a major shareholder of CH:CURE?
Currently, no hedge funds are holding shares in CH:CURE
CURE ETF Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.
Top 10 Holdings
Moderna
9.69%
Vertex Pharmaceuticals Inc.
7.36%
Regeneron Pharmaceuticals
6.98%
Natera Inc.
6.76%
Veeva Systems Inc
6.76%
Illumina
6.15%
Dexcom
5.27%
Guardant Health
4.36%
Alnylam Pharmaceuticals
3.73%
Biontech Se Sponsored Adr
3.59%
Total60.67%
See All Holdings











